Register now

11111

General Information

  • Home
  • General Information

11111

ABOUT EVENT

Welcome to the 3rd Global Conference for World Pneumonia Day

Dear Colleagues, Friends, and General Public

It is a great pleasure –as the Global Conference Chair– to welcome you to the 3rd Global Conference for World Pneumonia Day, which takes place on November 10th, 2023 in Lima, Peru.

Pneumonia is the world’s biggest infectious killer, claiming 2.5 million lives, including 672,000 children under five years, in 2019 alone. That is one person dying every 13 seconds. Yet pneumonia remains a neglected disease. The COVID-19 pandemic has clearly placed respiratory tract infections at the centre of public health. In 2021, the estimated burden of deaths from respiratory infections, including COVID-19, was a massive 6 million.

With the theme “Reducing the burden of pneumonia in the Americas”, the 3rd Global Conference for World Pneumonia Day will explore the impact of pneumonia in a region where 323,000 people are dying each year, including 20,700 children under five years of age.

Pneumonia is a preventable disease. Unless we take action now to reduce pneumonia deaths, and with a high risk of another respiratory infection pandemic, millions more adults and children will die from pneumonia over the next decade.

Dr. Catia Cilloniz
Chairman of the 3rd Global Conference for World Pneumonia Day

Where

Lima, Peru and Virtually

When

November 10, 2023 08:00 AM
Register Now

11111

Great Speakers

Speakers from multiple parts of the world gathered in one place

Experience

Speakers with extensive experience and a relevant academic program

Networking

Contact with hundreds of colleagues specialized in different areas of health

Attendance

From anywhere in the world, you only need a device and internet connection

Dear Colleagues & Friends,

As Chairpersons of the 4th Global Conference for World Pneumonia Day 2024, it gives us great pleasure to invite you to join our event, which is part of the Worldwide Pneumonia Awareness Campaign-Pneumolight, with the support of the Philippine College of Physicians (PCP) in Manila, to be held on 9 November 2024.

Despite the global impact of the COVID-19 pandemic, pneumonia remains a neglected disease. Sadly, the 2021 Global Burden of Disease report showed that 2.1 million people died of pneumonia in that year; children under five years and adults over 70 continued to be the most vulnerable populations, with more than 500,000 and 1 million pneumonia-related deaths respectively. Another important problem is the impact of antimicrobial resistance (AMR); according to the 2019 GBD report, 1.27 million deaths were attributable to bacterial AMR in that year, and one in five deaths caused by AMR occurred in children under five years old. The 2019 GBD report identified Streptococcus pneumoniae as the most frequent pathogen causing pneumonia,
contributing to 16% of the deaths attributable to AMR.

Although great progress continues to be made, the worldwide burden of pneumonia remains huge. We need everyone to know about the disease and its impact on our health, and above all, we need to show that it can be prevented. Pneumonia must be recognized as a major global health problem. Until this recognition comes, we will continue our attempts to educate and prevent, because we know that education is prevention and prevention saves lives.

Working together, we can move the world because we know that if we fight, we can win!!!!

Yours sincerely,

Catia Cilloniz
Guinevere Dy-Agra
Rodolfo S. Pagcatipunan Jr

This will close in 0 seconds

This will close in 0 seconds

This will close in 0 seconds

Louis Bont, MD, PhD

Louis Bont, MD, PhD, is a Pediatric Infectiologist-Immunologist and the head of the Pediatric Department at the University Medical Center Utrecht, The Netherlands. He is the founding chairman of ReSViNET, an international respiratory syncytial virus (RSV) research consortium. His specific research interests include RSV pathogenesis and the burden of disease.

Dr. Bont's work focuses on unraveling the role of neutrophils, RSV-related mortality, and long-term airway disease following RSV infection. He is the lead investigator of the INFORM study, a large prospective global clinical virology study that aims to uncover the molecular epidemiology of RSV in over 2000 children. He also leads the RSV GOLD mortality registry, funded by the Bill and Melinda Gates Foundation.

His group collaborates with the World Health Organization on RSV surveillance and vaccine development. Dr. Bont’s research emphasizes clinical and translational mechanisms of disease and the identification of intervention targets for RSV bronchiolitis. He has been the lead author of over 300 publications in peer-reviewed medical journals.

Additionally, he founded the Training of Upcoming Leaders in Pediatric Science (TULIPS), a career training network for clinician scientists in the field of Child Health.

This will close in 0 seconds

This will close in 0 seconds